Performance of Ovarian Cancer Diagnostic Tests
Author Information
Author(s): Langmár Z, Németh M, Székely B, Borgulya G
Primary Institution: Semmelweis University, Budapest, Hungary
Hypothesis
Do HE4 and ROMA improve the detection of malignant ovarian disease compared to CA125 alone?
Conclusion
The study suggests that HE4 and ROMA do not significantly improve the detection of ovarian cancer compared to CA125 alone.
Supporting Evidence
- HE4 and ROMA did not increase the detection of malignant disease compared to CA125 alone.
- The AUC values for ROMA, CA125, and HE4 showed a trend for better performance for ROMA.
- Van Gorp's study had a higher cancer incidence rate compared to other studies.
Takeaway
The study looked at different tests to find ovarian cancer, but found that adding new tests didn't help more than the old one.
Methodology
The study compared the diagnostic performance of serum tumour markers CA125 and HE4 and the ROMA clinical risk stratification tool using serum samples from patients with ovarian mass.
Potential Biases
Incomplete description of study objectives and population could lead to bias.
Limitations
The study lacked a clear explanation of sample size calculation and power, which may affect the validity of the results.
Participant Demographics
The study included a high cancer incidence rate and a higher proportion of postmenopausal women compared to other studies.
Statistical Information
Confidence Interval
AUC(ROMA)–AUC(CA125)=0.021 (−0.009 to 0.051)
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website